(Q78082941)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10432169%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

title

In vitro inhibition of glucose phosphorylation by an aldose-reductase inhibitor (Tolrestat) in some non-insulin-sensitive rabbit tissues (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10432169%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

author name string

S Iannello

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10432169%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

A Cavaleri

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10432169%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

M Camuto

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10432169%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

F Belfiore

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10432169%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

publication date

1 March 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10432169%20AND%20SRC:MED&resulttype=core&format=json

Journal of Diabetes and its Complications

10 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10432169%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10432169%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10432169%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

page(s)

68-73

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10432169%20AND%20SRC:MED&resulttype=core&format=json

Capillaries phosphorylate glucose in a concentration-dependent manner through a glucokinase-like enzyme: a study in the eel

10 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2898%2900027-0

7 January 2021

A glucokinase-like enzyme carries out glucose phosphorylation in capillaries of normal and spontaneously hyperglycemic rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2898%2900027-0

7 January 2021

Rabbit optic nerve phosphorylates glucose through a glucokinase-like enzyme: studies in normal and spontaneously hyperglycemic animals

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2898%2900027-0

7 January 2021

Rabbit lens and retina phosphorylate glucose through a glucokinase-like enzyme: study in normal and spontaneously hyperglycemic animals

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2898%2900027-0

7 January 2021

Hyperglycemia as a cause of diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2898%2900027-0

7 January 2021

Banting lecture 1986. Does a common mechanism induce the diverse complications of diabetes?

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2898%2900027-0

7 January 2021

Tissue Glycolytic and Gluconeogenic Enzyme Activities in Mildly and Moderately Diabetic Rats: Influence of Tolbutamide Administration

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2898%2900027-0

7 January 2021

Purification and properties of adenosine 5′-triphosphate-d-glucose 6-phosphotransferase from rat liver

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2898%2900027-0

7 January 2021

Factors underlying significant underestimations of glucokinase activity in crude liver extracts: physiological implications of higher cellular activity.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2898%2900027-0

7 January 2021

Tolrestat pharmacokinetics in rat peripheral nerve

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2898%2900027-0

7 January 2021

Aldose reductase inhibition. The chemical key to the control of diabetic retinopathy?

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2898%2900027-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2898%2900027-0

7 January 2021

The efficacy of aldose reductase inhibitors on polyol accumulation in human lens and retinal pigment epithelium in tissue culture

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2898%2900027-0

7 January 2021

Effects of aldose reductase inhibitors on the progression of nerve damage

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2898%2900027-0

7 January 2021

Aldose reductase inhibitors and the complications of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2898%2900027-0

7 January 2021

The efficacy of tolrestat in the treatment of diabetic peripheral neuropathy. A meta-analysis of individual patient data

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2898%2900027-0

7 January 2021

Tolrestat improves nerve regeneration after crush injury in streptozocin-induced diabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2898%2900027-0

7 January 2021

Chapter 17. Aldose Reductase Inhibitors as a New Approach to the Treatment of Diabetic Complications

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2898%2900027-0

7 January 2021

The pharmacology of aldose reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2898%2900027-0

7 January 2021

The effects of a new aldose reductase inhibitor (tolrestat) in galactosemic and diabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2898%2900027-0

7 January 2021

Effect of tolrestat on red blood cell sorbitol levels in patients with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2898%2900027-0

7 January 2021

Prevention of neural myoinositol depletion in diabetic rats by aldose reductase inhibition with tolrestat

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2898%2900027-0

7 January 2021

Glucose-induced microvascular functional changes in nondiabetic rats are stereospecific and are prevented by an aldose reductase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2898%2900027-0

7 January 2021

Effects of aldose reductase inhibitors on the progression of nerve fiber damage in diabetic neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2898%2900027-0

7 January 2021

Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. The Tolrestat Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2898%2900027-0

7 January 2021

A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2898%2900027-0

7 January 2021

Nerve conduction measures in mild diabetic neuropathy in the Early Diabetes Intervention Trial: the effects of age, sex, type of diabetes, disease duration, and anthropometric factors. Tolrestat Study Group for the Early Diabetes Intervention Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2898%2900027-0

7 January 2021

Frequency of median mononeuropathy in patients with mild diabetic neuropathy in the early diabetes intervention trial (EDIT). Tolrestat Study Group For Edit (Early Diabetes Intervention Trial)

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2898%2900027-0

7 January 2021

Diabetic regulation and its relationship to microangiopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2898%2900027-0

7 January 2021

Diabetic control and microvascular complications: the near-normoglycaemic experience

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2898%2900027-0

7 January 2021

Hyperglycemia, Polyol Metabolism, and Complications of Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2898%2900027-0

7 January 2021

The effect of aldose reductase and its inhibition on sugar cataract formation

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2898%2900027-0

7 January 2021

Inhibition of erythrocyte anion exchange by tolrestat, an inhibitor of aldose reductase

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2898%2900027-0

7 January 2021

The effect of aldose reductase inhibitor Statil (ICI 128436) on the glucose over-utilization in kidney of diabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2898%2900027-0

7 January 2021

Glycolytic pathway, redox state of NAD(P)-couples and energy metabolism in lens in galactose-fed rats: effect of an aldose reductase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2898%2900027-0

7 January 2021

Purification and characterization of human-brain aldose reductase.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2898%2900027-0

7 January 2021

Activation of human erythrocyte, brain, aorta, muscle, and ocular tissue aldose reductase.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2898%2900027-0

7 January 2021

10.1016/S1056-8727(98)00027-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10432169%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

1 reference